Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL6906927 | 1.00 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL27206783 | 1.00 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL27781966 | 0.97 | TSHR (0.59) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL29824737 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL6332969 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL263200 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL4111185 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL9474227 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL11054858 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL8467361 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4507722-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | Bluewillow Biologics, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | claimed |
| WO-2023200764-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-10-19 | — | — | WO | claimed |
| EP-2278997-B1 | NANOEMULSION INFLUENZA VACCINE | NANOBIO CORP (US) | 2016-08-10 | — | — | EP | claimed |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2012-11-01 | — | — | US | claimed |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2012-08-30 | — | — | US | claimed |
| US-8226965-B2 | Methods of treating fungal, yeast and mold infections | NANOBIO CORPORATION (US) | 2012-07-24 | — | — | US | claimed |
| US-20120064136-A1 | ANTI-AGING AND WRINKLE TREATMENT METHODS USING NANOEMULSION COMPOSITIONS | NANOBIO CORPORATION | 2012-03-15 | — | — | US | claimed |
| EP-2349209-A2 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME | Nanobio Corporation (US) | 2011-08-03 | — | — | EP | claimed |
| EP-2293787-A1 | NANOEMULSIONS FOR TREATING FUNGAL, YEAST AND MOLD INFECTIONS | Nanobio Corporation (US) | 2011-03-16 | — | — | EP | claimed |
| US-20100092526-A1 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME | NANOBIO CORPORATION | 2010-04-15 | — | — | US | claimed |
| WO-2010036938-A2 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME | NANOBIO CORPORATION (US) | 2010-04-01 | — | — | WO | claimed |
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2010-03-25 | — | — | US | claimed |
| US-20090304799-A1 | NANOEMULSION INFLUENZA VACCINE | NANOBIO CORPORATION | 2009-12-10 | — | — | US | claimed |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| WO-2009132342-A1 | NANOEMULSIONS FOR TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2009132343-A1 | NANOEMULSIONS FOR TREATING ONCHOMYCOSIS | NANOBIO CORPORATION (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2009131995-A1 | NANOEMULSION INFLUENZA VACCINE | NANOBIO CORPORATION (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2009129470-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | DPM1, ERG28, POLR1C | TSHR 4789/4885LMNA 3448/4885CYP3A4 1910/4885 |
| US-20100092526-A1 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME | CFTR, CCL11, ELANE | TSHR 4568/4885LMNA 4380/4885CYP3A4 3765/4885 |
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | TSHR 4826/4885LMNA 3805/4885CYP3A4 4587/4885 |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | TSHR 4862/4885LMNA 3248/4885CYP3A4 1201/4885 |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | TSHR 4826/4885LMNA 3805/4885CYP3A4 4587/4885 |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | TSHR 4862/4885LMNA 3248/4885CYP3A4 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.